DOCSLIB.ORG

Genome Research Limited

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Genome Research Limited Genome Research Limited Annual Report and Financial Statements For year ended 30 September 2020 Introduction 5 Chief Executive’s introduction 6 Timeline of highlights 2 Introduction Trustees’ Report Financial Statements 8 Trustees’ Report 8 Objectives and activities 9 Strategic report 9 Achievements and performance 14 Section 172 statement 16 Financial Review 19 Plans for future periods 20 Principal risks and uncertainties 20 Structure, governance and management 23 Employee engagement statement 25 Statement of Directors’ responsibilities 26 Independent Auditor’s report Financial Statements 28 Statement of Financial Activities 29 Balance Sheet 30 Notes to the Financial Statements 47 Reference and Administrative Information Genome Research Limited Annual Report and Financial Statements for Year Ended 30 September 2020 3 4 Genome Research Limited Annual Report and Financial Statements for Year Ended 30 September 2020 Introduction Trustees’ Report Financial Statements Chief Executive’s Introduction Genome Research Limited (“GRL”) The coronavirus pandemic continues to have encompasses a number of activities a profound impact on our ability to deliver undertaken by our operation at the Wellcome genomic science. The Wellcome Sanger Genome Campus. All of these activities work Institute and Connecting Science closed in in the fields of Genomes and Biodata and March 2020 to all but essential work. are very much interlinked. The three pillars of Research programmes and projects have activity are research, discourse, and slowed or paused, the quinquennial review enterprise and innovation which are site visit scheduled for June 2020 has been delivered by the Wellcome Sanger Institute postponed, and all training and engagement (“Sanger Institute”) and Connecting Science activities have become virtual. based at the Wellcome Genome Campus. Alongside these considerable challenges the As the former UK Chief Medical Officer Institute has committed £6.3 million of outlined in her report Health, our global asset funding to sequence 180,000 SARS-CoV-2 – partnering for progress we live in a global samples over the next year as its village where the health issues of one contribution to the COG-UK Consortium. country swiftly impact another. In this world, Over 200 staff volunteered to contribute to genomics – powered by open-access data this initiative, a real world demonstration of sharing - is central to delivering the rapid, the value of the UK science base, the insightful information needed for effective Sanger Institute scientific infrastructure and healthcare delivery and to shape successful the value of genomics to aid decision making therapies. and policy development. As evidenced by the outbreak of the COVID- The Campus has been converted into a 19 coronavirus, seamless and open sharing ‘COVID secure’ workplace, our genome of genomic data is powering the worldwide sequencing platforms are close to full race to develop vaccines and guide capacity once again, and we hope that other international public health responses. Here data generation platforms will follow shortly. at the Institute, this openness has always Science and collaboration will be the solution been part of our culture. We analyse malaria to this pandemic and at GRL we will play our parasite genomes from both neighbouring part. countries and continents to track the emergence and spread of drug resistance, guiding public health strategies. By successfully pooling datasets on cancer samples, databases and analysis across continents we are revealing the causes and potential treatments for tumours, driving the development of precision, personalised Professor Sir Mike Stratton, medicine. Director, Wellcome Sanger Institute Chief Executive, Wellcome Genome Over the last year the Wellcome Sanger Institute had some major successes, a Campus collaborative award from Wellcome to deliver the first phase of the UK wide Darwin Tree of Life Project, funding from the Bill and Melinda Gates Foundation to deliver malaria surveillance at actionable scale, and a raft of documents were submitted to Wellcome in December 2019 to support our 5-year (2021- 2026) funding request. Genome Research Limited Annual Report and Financial Statements for Year Ended 30 September 2020 5 Sanger Institute joins COG-UK Red and grey consortium to Resurrected squirrel Cancer sequence ancient gene genomes Dependency Map COVID-19 virus explains malaria’s sequenced for uses CRISPR to spread jump from first time narrow drug gorillas to target list humans Gosia Trynka Jeremy Farrar becomes Open New malaria becomes Targets’ drug targets Head of Experimental identified in Genome Director liver stage of Research life cycle Limited Board Oct Nov Dec Jan Feb Mar First cell map Mouse models Cancer map for shows how the reveal 140+ uncharted 99% liver develops genes linked to of genome immune system made by Global control Pan-Cancer Colon crypts and Project lasers reveal Root of pathway to childhood Gut cell atlas cancer kidney cancer maps how discovered bacteria and immune cells Darwin Tree of interact Life project Never too late to quit – launches ex-smokers’ lungs repair genetic damage Wellcome Genome Campus temporarily closes, critical research continues 6 Introduction Trustees’ Report Financial Statements Genomic surveillance of antibiotic resistance established in the Sanger researchers Philippines join UK Consortium to unlock immune system’s role in Key nose cells COVID-19 identified as Sanger likely COVID- Innovations Sixth form collaboration 19 virus entry Team launches student to explore points BIODATA genomics text marine and interactive talks book published freshwater ecosystems 6 Sanger researchers Secondary and Public trust on recognised by primary school data vital for Academy of digital home genomic Medical Sciences learning packs research released Apr May Jun Jul Aug Sep Microbiotica Seeds of uterine collaborates on Mentoring cancer sown landmark cancer podcast supports early in life microbiome early career studies researchers Cell atlas Sanger extends maps the postdoctoral human heart First cell atlas funding to cover DECIPHER of mosquito COVID-19 opens up immune cells lockdown whole genome for rare disease diagnoses Bulk of genetic Pharma-Academia variation collaboration responsible for brings personalised blood cell health medicine closer revealed Genome Research Limited awarded Athena SWAN Silver Genome Research Limited Annual Report and Financial Statements for Year Ended 30 September 2020 7 Trustees’ Report The Directors of Genome Research Limited (“the Charitable Company” ) who are also the Trustees of Genome Research Limited for the purposes of the Charities Act 2011, present their Annual Report (including the Directors’ Report and Strategic Report) and audited Financial Statements for the year ended 30 September 2020. Objectives and activities Genome Research Limited’s (“GRL”) objectives are: Advance understanding of biology using genome sequences and biodata. Apply genome science for human sequences to increase understanding of pathogen evolution, the phenotypic health and other societal benefits. human and pathogen biology in order to consequences of genome variation improve human health. and the processes which cause Foster discussion of the scientific, mutations. We will generate deeper medical and wider implications of To achieve this goal, we conduct basic understanding of the genetic causes, genomes. and translational research delivered pathogenesis and epidemiology of across five research programmes and human disease, of human Vision two associate research programmes: development and ageing and of Motivated by the remarkable Cancer, Ageing and Somatic Mutation human gene function. We aim to challenges and opportunities identify therapeutic and vaccine presented to 21st century science by Cellular Genetics targets and to explore the genomic genome sequences, the ambition of changes influencing sensitivity and GRL over the next two decades is to Human Genetics resistance to such agents. strengthen its well-established The Sanger Institute sits at the centre scientific foundations and to build on Parasites and Microbes of a global network of science, them, such that the Wellcome Tree of Life engaging proactively with Genome Campus becomes an researchers external to the Institute, international centre for scientific, Health Data Research UK (Associate enabling and empowering their business, cultural and educational Research Programme) science and extending our scientific activities emanating from Genomes repertoire through their biological and Biodata. Open Targets (Associate Research insights and questions. A major Programme) The objectives are delivered via three priority of our research portfolio is the main activities as follows: Our scientific niche is in large-scale, scientific questions arising from the high-throughput biology, often health issues facing low- and middle- Research (via the Sanger Institute) incorporating systematic genome-wide income countries. We continue to Discourse (via Connecting Science) screens. This is enabled by major data champion the policy of early and generation platforms in DNA open data release and ensure Enterprise and Innovation. sequencing, cellular genetics and resources generated through our mouse genetics with an accompanying research enable the research of Mission large IT platform supporting others through publicly accessible Sanger Institute computational data interpretation and databases. analysis. One of the major challenges and Connecting
Load more

Recommended publications
  • Wellcome Trust Annual Report and Financial Statements 2017 Contents
    Annual Report and Financial Statements 2017 2 Wellcome Trust Annual Report and Financial Statements 2017 Contents Report from the Chair and the Director 5 Trustee’s Report 8 What we do 8 Review of Charitable Activities 9 Review of Investment Activities 18 Financial Review 29 Structure and Governance 34 Risk Management 37 Remuneration Report 40 Audit Committee Report 43 Independent Auditor’s Report 45 Financial Statements 58 Consolidated Statement of Financial Activities 58 Consolidated Balance Sheet 59 Statement of Financial Activities of the Trust 60 Balance Sheet of the Trust 61 Consolidated Cash Flow Statement 62 Notes to the Financial Statements 63 Reference and Administrative Details 117 3 Wellcome Trust Annual Report and Financial Statements 2017 “ At Wellcome, we believe in the power of ideas to improve health” Jeremy Farrar Director 4 Wellcome Trust Annual Report and Financial Statements 2017 Report from the Chair and the Director “Our core approach is funding people to explore great ideas, at every step of the way from discovery to impact” At Wellcome, we believe in the power of ideas to improve cause of maternal mortality in the world. It also includes health. Funded from our independent investment portfolio, supporting research in the humanities and social sciences, we support thousands of scientists and researchers in more such as a project which this year published ethical guidelines than 70 countries, as well as innovators, educators and artists. for involving pregnant women in Zika vaccine research. Together, we take on big problems, fuel imaginations and spark And resources like the Human Induced Pluripotent Stem Cell debate, working always to achieve better health for everyone.
    [Show full text]
  • Uniprot at EMBL-EBI's Role in CTTV
    Barbara P. Palka, Daniel Gonzalez, Edd Turner, Xavier Watkins, Maria J. Martin, Claire O’Donovan European Bioinformatics Institute (EMBL-EBI), European Molecular Biology Laboratory, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SD, UK UniProt at EMBL-EBI’s role in CTTV: contributing to improved disease knowledge Introduction The mission of UniProt is to provide the scientific community with a The Centre for Therapeutic Target Validation (CTTV) comprehensive, high quality and freely accessible resource of launched in Dec 2015 a new web platform for life- protein sequence and functional information. science researchers that helps them identify The UniProt Knowledgebase (UniProtKB) is the central hub for the collection of therapeutic targets for new and repurposed medicines. functional information on proteins, with accurate, consistent and rich CTTV is a public-private initiative to generate evidence on the annotation. As much annotation information as possible is added to each validity of therapeutic targets based on genome-scale experiments UniProtKB record and this includes widely accepted biological ontologies, and analysis. CTTV is working to create an R&D framework that classifications and cross-references, and clear indications of the quality of applies to a wide range of human diseases, and is committed to annotation in the form of evidence attribution of experimental and sharing its data openly with the scientific community. CTTV brings computational data. together expertise from four complementary institutions: GSK, Biogen, EMBL-EBI and Wellcome Trust Sanger Institute. UniProt’s disease expert curation Q5VWK5 (IL23R_HUMAN) This section provides information on the disease(s) associated with genetic variations in a given protein. The information is extracted from the scientific literature and diseases that are also described in the OMIM database are represented with a controlled vocabulary.
    [Show full text]
  • Uman Enome News
    uman enome news ISSN:l050-6101 Vol. 3, No.1, May 1991 DOE Holds Contractor-Grantee Workshop Physical Mapping Efforts Going Well; Gels Increasing Sequencing Efficiency he DOE Human Genome Prograll1 held its second Contractor-Grantee Workshop Charles R. Cantor and HGMIS gratefully Tin Santa Fe, New Mexico, on February l7-W. More than 200 program-sponsored acknowledge contribu­ scientists attended the meeting, in addition to invited guests and industry represen­ tions to this article by tatives. DOE-supported human genome research projects are conducted at 7 DOE Elbert W. Branscomb, national laboratories (including its 3 human genome centers), 37 major universities, Anthony V. Carrano, and 32 companies through collaborations and awards. Projects were represented by Leroy E. Hood, oral presentations or posters. Robert K. Moyzis, and Robert J. Robbins. Six platform sessions focused on the more focus is needed on the immediate following: informatics needs of ongoing biology projects. • physical mapping progress, Many parallel efforts under way in cloning, • large DNA fragment cloning, informatics, mapping, and sequencing will • strategies for preparing samples for further improve the technologies required for efficient DNA sequencing, genomics. Program participants feel that this situation is healthy at present and that a few • new methods for a variety of genome efforts, • DNA sequencing instrumentation, and In This fssue .•. • database and computer algorithm needs for existing or projected genome Page Genome News research. 1 DOE Holds Contractor-Grantee Workshop David Galas, Associate Director, Office of 5 LANL, Life Technologies Approve CRADA Health and Environmental Research (OHER), 6 Conncil on Competitiveness Urges Action spoke about the relationship between the 7 Moore Calls Tech Transfer Critical to Fntnre' Human Genome Program and other OHER 8 NIH Discusses eDNA Role with Invited Group programs.
    [Show full text]
  • 100000 Genomes and Genomics England
    100,000 Genomes & Genomics England Tim Hubbard Genomics England King’s College London, King’s Health Partners Wellcome Trust Sanger Institute Global Leaders in Genomic Medicine Washington 8-9th January 2014 UK Health System 101 • Four separate health services – NHS England – NHS Wales – NHS Scotland – Health & Social Care in Northern Ireland (HSC) • NHS (England) – ~1.4 million employees – ~£110 billion annual budget • Structure in England changed 1st April 2013 https://www.gov.uk/government/organisations/department-of-health Linking Health data to Research Clinical Data Healthcare Professional World Genotype Electronic Health Record Whole Genome Sequencing Phenotype Electronic Genomic Biology Health Data World Records Reference Genotype and genome sequence Phenotype ~3 gigabytes relationship capture EBI: repositories (petabytes of genome sequence data) Human sequence data Sanger: sequencing repositories (1000 genomes, uk10K) Steps in UK towards E-Health Research, Genomic Medicine • Health data to Research – 2006 Creation of OSCHR • Increase coordination between funders: MRC and NIHR – 2007 OSCHR E-health board • Enable research access to UK EHR data • Build capacity for research on EHR data • Genomics to Health – 2009 House of Lords report on Genomic Medicine – 2010 Creation of Human Genomic Strategy Group (HGSG) 2011: UK Life Sciences Strategy No10: http://www.number10.gov.uk/news/uk-life-sciences-get-government-cash-boost/ BIS/DH: http://www.dh.gov.uk/health/2011/12/nhs-adopting-innovation/ Linking Health data to Research Clinical Data
    [Show full text]
  • Functional Effects Detailed Research Plan
    GeCIP Detailed Research Plan Form Background The Genomics England Clinical Interpretation Partnership (GeCIP) brings together researchers, clinicians and trainees from both academia and the NHS to analyse, refine and make new discoveries from the data from the 100,000 Genomes Project. The aims of the partnerships are: 1. To optimise: • clinical data and sample collection • clinical reporting • data validation and interpretation. 2. To improve understanding of the implications of genomic findings and improve the accuracy and reliability of information fed back to patients. To add to knowledge of the genetic basis of disease. 3. To provide a sustainable thriving training environment. The initial wave of GeCIP domains was announced in June 2015 following a first round of applications in January 2015. On the 18th June 2015 we invited the inaugurated GeCIP domains to develop more detailed research plans working closely with Genomics England. These will be used to ensure that the plans are complimentary and add real value across the GeCIP portfolio and address the aims and objectives of the 100,000 Genomes Project. They will be shared with the MRC, Wellcome Trust, NIHR and Cancer Research UK as existing members of the GeCIP Board to give advance warning and manage funding requests to maximise the funds available to each domain. However, formal applications will then be required to be submitted to individual funders. They will allow Genomics England to plan shared core analyses and the required research and computing infrastructure to support the proposed research. They will also form the basis of assessment by the Project’s Access Review Committee, to permit access to data.
    [Show full text]
  • Genomics England and Sciencewise Evaluation of a Public Dialogue On
    Genomics England and Sciencewise Evaluation of a public dialogue on Genomic Medicine: Time for a new social contract? Evaluation report June 2019 Quality Management URSUS Consulting Ltd has quality systems which have been assessed and approved to BS EN IS9001:2008 (certificate number GB2002687). Creation / Revision History Issue / revision: 3 Date: 19/6/2019 Prepared by: Anna MacGillivray Authorised by: Anna MacGillivray Project number: U.158 File reference: Genomics England/genomic medicine draft evaluation report 19.6.2019 URSUS CONSULTING LTD 57 Balfour Road London N5 2HD Tel. 07989 554 504 www.ursusconsulting.co.uk _________________________________________________________________________________________ URSUS CONSULTING GENOMICS ENGLAND AND SCIENCEWISE 2 Glossary of Acronyms ABI Association of British Insurers AI Artificial Intelligence APBI Association of British Pharmaceutical Industry BEIS (Department of) Business, Energy and Industrial Strategy BME Black and Minority Ethnic CMO Chief Medical Officer CSO (NHS) Chief Scientific Officer DA Devolved Administration DHSC Department of Health and Social Care FTE Full Time Equivalent GDPR General Data Protection Regulation GE Genomics England GG Generation Genome report GMS Genomic medicine service GMC General Medical Council NHS National Health Service OG Oversight Group REA Rapid Evidence Assessment SEG Socio economic group SGP Scottish Genomes Partnership SoS Secretary of State SSAC Scottish Science Advisory Committee SLT Senior Leadership Team UKRI UK Research and Innovation WGS Whole Genome Sequencing _________________________________________________________________________________________ URSUS CONSULTING GENOMICS ENGLAND AND SCIENCEWISE 3 EXECUTIVE SUMMARY Introduction This report of the independent evaluation of a public dialogue on Genomic Medicine: Time for a new social contract? has been prepared by URSUS Consulting Ltd on behalf of Genomics England (GE) and Sciencewise1.
    [Show full text]
  • Jeremy Farrar
    FEATURE The BMJ THE BMJ INTERVIEW BMJ: first published as 10.1136/bmj.n459 on 19 February 2021. Downloaded from [email protected] Cite this as: BMJ 2021;372:n459 http://dx.doi.org/10.1136/bmj.n459 Jeremy Farrar: Make vaccine available to other countries as soon as Published: 19 February 2021 our most vulnerable people have received it The SAGE adviser and Wellcome Trust director tells Mun-Keat Looi how the UK government acted too slowly against the pandemic, about the perils of vaccine nationalism, and why he is bullish about controlling covid variants Mun-Keat Looi international features editor “Once the UK has vaccinated our most vulnerable among healthcare workers. We had no human communities and healthcare workers we should make immunity, no diagnostics, no treatment, and no vaccines available to other countries,” insists the vaccines. infectious disease expert Jeremy Farrar. This could Every country should have acted then. Singapore, avert further public health and economic disaster, China, and South Korea did. Yet most of Europe and he says, describing it as “enlightened self-interest, North America waited until the middle of March, and as well as the right ethical thing to do.” that defined the first wave. Countries including the In April 2020, soon after the first UK lockdown began, UK were unwilling to act early, before they felt Farrar predicted that the UK would have one of the comfortable; were unwilling to go deeper than they worst covid-19 death rates in Europe. As a member thought they had to; and were unwilling to keep of the Scientific Advisory Group for Emergencies restrictions in place for as long as was needed.
    [Show full text]
  • Female Fellows of the Royal Society
    Female Fellows of the Royal Society Professor Jan Anderson FRS [1996] Professor Ruth Lynden-Bell FRS [2006] Professor Judith Armitage FRS [2013] Dr Mary Lyon FRS [1973] Professor Frances Ashcroft FMedSci FRS [1999] Professor Georgina Mace CBE FRS [2002] Professor Gillian Bates FMedSci FRS [2007] Professor Trudy Mackay FRS [2006] Professor Jean Beggs CBE FRS [1998] Professor Enid MacRobbie FRS [1991] Dame Jocelyn Bell Burnell DBE FRS [2003] Dr Philippa Marrack FMedSci FRS [1997] Dame Valerie Beral DBE FMedSci FRS [2006] Professor Dusa McDuff FRS [1994] Dr Mariann Bienz FMedSci FRS [2003] Professor Angela McLean FRS [2009] Professor Elizabeth Blackburn AC FRS [1992] Professor Anne Mills FMedSci FRS [2013] Professor Andrea Brand FMedSci FRS [2010] Professor Brenda Milner CC FRS [1979] Professor Eleanor Burbidge FRS [1964] Dr Anne O'Garra FMedSci FRS [2008] Professor Eleanor Campbell FRS [2010] Dame Bridget Ogilvie AC DBE FMedSci FRS [2003] Professor Doreen Cantrell FMedSci FRS [2011] Baroness Onora O'Neill * CBE FBA FMedSci FRS [2007] Professor Lorna Casselton CBE FRS [1999] Dame Linda Partridge DBE FMedSci FRS [1996] Professor Deborah Charlesworth FRS [2005] Dr Barbara Pearse FRS [1988] Professor Jennifer Clack FRS [2009] Professor Fiona Powrie FRS [2011] Professor Nicola Clayton FRS [2010] Professor Susan Rees FRS [2002] Professor Suzanne Cory AC FRS [1992] Professor Daniela Rhodes FRS [2007] Dame Kay Davies DBE FMedSci FRS [2003] Professor Elizabeth Robertson FRS [2003] Professor Caroline Dean OBE FRS [2004] Dame Carol Robinson DBE FMedSci
    [Show full text]
  • Dr Sophia Skyers Director, CIBS IQ Research
    CIBS IQ Research Inclusion by Dialogue and Design 100,000 Genomes Project Black African and Black Caribbean Communities A Qualitative Exploration of Views on Participation Report Author: Dr Sophia Skyers Director, CIBS IQ Research June 2018 Acknowledgements Dr Sophia Skyers, the author, would like to thank all of the focus group participants, event attendees and radio panel members for the invaluable contribution that they have made to informing this report and to shaping its recommendations. The participation of the community and the critical exchange of views is vitally important, and projects such as these cannot be undertaken without that active engagement. The author would also like to thank Can-Survive UK, BME Cancer Communities, Genomics England, and all of the healthcare professionals, geneticists, genetics researchers, and stakeholders from a range of organisations for sharing their knowledge, experience and insights so openly, and to Dr Rohan Morris for sharing his experience on ethnicity and access in relation to clinical research. 2 Table of Contents Executive Summary 4 100,000 Genomes Project 4 1. Introduction and background 9 2. About the 100,000 Genomes Project 9 3. Purpose and approach to conducting the study 13 4. Discussion oF Findings 15 a) Interviews with stakeholders 15 b) Focus groups, awareness-raising events and media campaigns 24 5. Conclusion, synthesis and recommendations 38 Appendix A – Focus Groups 41 Appendix B – Awareness Raising Events and Radio Campaigns 42 Appendix B – Stakeholder Interviews 43 Appendix B – ReFerences 44 3 Executive Summary 100,000 Genomes Project The 100,000 Genomes Project is aiming to sequence 100,000 whole genomes from approximately 70,000 consented NHS patients in the UK with all types of cancer, and rare diseases, as well as patients’ family members, as these diseases are strongly linked to changes in the genome.
    [Show full text]
  • Clinical Molecular Genetics in the Uk C.1975–C.2000
    CLINICAL MOLECULAR GENETICS IN THE UK c.1975–c.2000 The transcript of a Witness Seminar held by the History of Modern Biomedicine Research Group, Queen Mary, University of London, on 5 February 2013 Edited by E M Jones and E M Tansey Volume 48 2014 ©The Trustee of the Wellcome Trust, London, 2014 First published by Queen Mary, University of London, 2014 The History of Modern Biomedicine Research Group is funded by the Wellcome Trust, which is a registered charity, no. 210183. ISBN 978 0 90223 888 6 All volumes are freely available online at www.history.qmul.ac.uk/research/modbiomed/ wellcome_witnesses/ Please cite as: Jones E M, Tansey E M. (eds) (2014) Clinical Molecular Genetics in the UK c.1975–c.2000. Wellcome Witnesses to Contemporary Medicine, vol. 48. London: Queen Mary, University of London. CONTENTS What is a Witness Seminar? v Acknowledgements E M Tansey and E M Jones vii Illustrations and credits ix Abbreviations xi Ancillary guides xiii Introduction Professor Bob Williamson xv Transcript Edited by E M Jones and E M Tansey 1 Appendix 1 Photograph, with key, of delegates attending The Molecular Biology of Thalassaemia conference in Kolimbari, Crete, 1978 88 Appendix 2 Extracts from the University of Leiden postgraduate course Restriction Fragment Length Polymorphisms and Human Genetics, 1982 91 Appendix 3 Archival material of the Clinical Molecular Genetics Society 95 Biographical notes 101 References 113 Index 131 Witness Seminars: Meetings and Publications 143 WHAT IS A WITNESS SEMINAR? The Witness Seminar is a specialized form of oral history, where several individuals associated with a particular set of circumstances or events are invited to meet together to discuss, debate, and agree or disagree about their memories.
    [Show full text]
  • PDF of Connecting Science's 2017
    Connecting Science Wellcome Genome Campus Hinxton, Cambridgeshire CB10 1RQ wellcomegenomecampus.org/connectingscience Annual Review 2017/18 2 02 Contents DIRECTO R’S INTRODUCTION Connecting Science in twelve months 04 – 05 Global ambitions Have you had your say on your DNA? 10 – 1 1 Increasing global impact by tailoring training needs 12 – 13 Worm hunting in Colombia 14 – 16 Catalysing collaboration Bringing together scientific partners 20 – 21 First global event for genetic counsellors 22 – 23 Decoding genomes together 24 – 26 Snapshot: May 2017 to April 2018 27 – 32 Democratising genomics CONNECTING SCIENCE Blood, sweat and success – Implementing a gender balance policy 36 – 37 2017/18 ANNUAL REVIEW Science communication: remembering to listen 38 – 39 Exploring our world in the Genome Gallery 40 – 41 The mission of Connecting Science is simple: to enable team, the commitment and support of our many partners and everyone to explore genomic science and its impact on collaborators, and the financial support and encouragement research, health and society. Behind those simple words is of Wellcome. I am personally very thankful for all of those Wellcome Genome Campus: considerable complexity. The science itself is complex and things, and know that this support and energy often translates ever-changing, with new technologies being continually into life- or career-changing experiences for the tens of A hub of knowledge, learning, developed and put into practice in both research and thousands of people we engage with directly every year. healthcare. The work that we do is also deceptively and engagement complex, reaching audiences from primary schools to I hope that some of the stories highlighted in this Annual research scientists, NHS staff to patients and their families; Review give you a sense of the excitement we have in all Creating spaces for thinking 46 – 47 it spans the globe, and everything we do involves constant that we do.
    [Show full text]
  • The Metagenomic Data Life-Cycle: Standards and Best Practices Petra Ten Hoopen1, Robert D
    GigaScience, 6, 2017, 1–11 doi: 10.1093/gigascience/gix047 Advance Access Publication Date: 16 June 2017 Review REVIEW Downloaded from https://academic.oup.com/gigascience/article-abstract/6/8/gix047/3869082 by guest on 01 October 2019 The metagenomic data life-cycle: standards and best practices Petra ten Hoopen1, Robert D. Finn1, Lars Ailo Bongo2, Erwan Corre3, Bruno Fosso4, Folker Meyer5, Alex Mitchell1, Eric Pelletier6,7,8, Graziano Pesole4,9, Monica Santamaria4, Nils Peder Willassen2 and Guy Cochrane1,∗ 1European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SD, United Kingdom, 2UiT The Arctic University of Norway, Tromsø N-9037, Norway, 3CNRS-UPMC, FR 2424, Station Biologique, Roscoff 29680, France, 4Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies, CNR, Bari 70126, Italy, 5Argonne National Laboratory, Argonne IL 60439, USA, 6Genoscope, CEA, Evry´ 91000, France, 7CNRS/UMR-8030, Evry´ 91000, France, 8Universite´ Evry´ val d’Essonne, Evry´ 91000, France and 9Department of Biosciences, Biotechnologies and Biopharmaceutics, University of Bari “A. Moro,” Bari 70126, Italy ∗Correspondence address. Guy Cochrane, European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SD, UK. Tel: +44(0)1223-494444; E-mail: [email protected] Abstract Metagenomics data analyses from independent studies can only be compared if the analysis workflows are described ina harmonized way. In this overview, we have mapped the landscape of data standards available for the description of essential steps in metagenomics: (i) material sampling, (ii) material sequencing, (iii) data analysis, and (iv) data archiving and publishing. Taking examples from marine research, we summarize essential variables used to describe material sampling processes and sequencing procedures in a metagenomics experiment.
    [Show full text]